3.31

1.92% -0.07

Puma Biotechnology Inc (PBYI)

Overview News Price History Option Chain Financials Discussions Forecast

Puma Biotechnology Inc stock is traded at $3.31, with a volume of 139.48K. It is down -1.92% in the last 24 hours and up +4.25% over the past month. Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Previous Close:

$3.38

Open:

$3.34

24h Volume:

139.48K

Relative Volume:

0.36

Market Cap:

$164.06M

Revenue:

$230.47M

Net Income/Loss:

$30.28M

P/E Ratio:

5.4262

EPS:

0.61

Net Cash Flow:

$38.86M

1W Performance:

+2.47%

1M Performance:

+4.25%

6M Performance:

-2.21%

1Y Performance:

-12.99%

1-Day Range:

$3.255

$3.355

1-Week Range:

$3.255

$3.45

52-Week Range:

$2.225

$4.13

Puma Biotechnology Inc Stock (PBYI) Company Profile

Name

Puma Biotechnology Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

(424) 248-6500

Address

10880 WILSHIRE BLVD., LOS ANGELES, CA

Employee

172

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PBYI's Discussions on Twitter

Compare PBYI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PBYI Puma Biotechnology Inc	3.305	161.32M	230.47M	30.28M	38.86M	0.61
ONC Beone Medicines Ltd Adr	245.78	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	443.49	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	40.37M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.09	6.19B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.83	64.44B	14.09B	4.50B	2.96B	39.28

Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy
Jun-25-20	Resumed	BofA/Merrill	Underperform
Oct-08-19	Downgrade	Goldman	Neutral → Sell
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-10-19	Downgrade	Citigroup	Buy → Neutral
Jan-17-19	Initiated	Leerink Partners	Mkt Perform
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-17-18	Initiated	Goldman	Sell
May-11-18	Reiterated	Stifel	Buy
Nov-10-17	Reiterated	Citigroup	Buy
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform
Oct-02-17	Reiterated	Stifel	Buy
Sep-11-17	Reiterated	Credit Suisse	Outperform
Jul-10-17	Resumed	Leerink Partners	Outperform
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform
Mar-02-17	Reiterated	RBC Capital Mkts	Sector Perform

View All

Puma Biotechnology Inc Stock (PBYI) Latest News

May 28, 2025

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - sharewise

May 28, 2025

May 26, 2025

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance

May 26, 2025

May 20, 2025

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st

May 20, 2025

May 17, 2025

Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st

May 17, 2025